Johns Hopkins surgical oncologist Martin Makary is set to take on a significant role as the next commissioner of the U.S. Food and Drug Administration. With his extensive background in surgery and public policy research, he brings a unique perspective to the position. Makary has long been a vocal advocate for changes in the healthcare system, aiming to lower costs and reduce medical errors.

Appointment and Responsibilities

Once confirmed by the U.S. Senate, Makary will lead the federal agency responsible for ensuring the safety, efficacy, and security of various products. This includes human and veterinary drugs, biological products, medical devices, the safety of the food supply and cosmetics, and the regulation of tobacco products. The FDA, which has a substantial impact on the U.S. economy, plays a crucial role in protecting public health.

Johns Hopkins Medicine commended Makary's professional commitment and leadership in the medical field. His appointment is seen as an opportunity to work with a dedicated team at the FDA and bring about positive changes.

During the COVID-19 pandemic, Makary's voice was prominent. He was an early advocate for universal masking and vaccines but later expressed concerns about certain aspects of the response, such as vaccine mandates and prolonged school closures.

Research and Contributions

Makary specializes in surgical oncology and holds important leadership positions at Johns Hopkins. He directs the Evidence-based Medicine and Public Policy Research Group and has published over 300 scientific articles. His current research focuses on the underlying causes of disease, vulnerable populations, and the appropriateness of care.

He is a member of the National Academy of Medicine and has previously served in a leadership role at the World Health Organization's patient safety program. His books, including Unaccountable and The Price We Pay, have received significant recognition and awards.

In a May 2022 study published by BMJ Open, Makary highlighted the slow funding of COVID clinical studies by the NIH. He has also criticized the FDA for being too bureaucratic in its response.

Impact on the Healthcare System

Makary's work and ideas have the potential to significantly impact the healthcare system. His advocacy for cost reduction and improved efficiency has the potential to benefit patients and the healthcare industry as a whole.

His leadership at the FDA could lead to changes in the agency's culture and promote scientific advancement. By addressing issues such as bureaucracy and red tape, he aims to speed up the approval process for medical products and improve public health.

With his extensive experience and expertise, Makary is well-positioned to make a positive impact on the FDA and the healthcare landscape.